To the full analysis
Intco Medical Technology Stock: Growth
300677.SZIntco Medical Technology reported $1.49B in revenue for fiscal 2025, up 4.2% on the prior year, down 6.4% a year on average over up to five years. That makes three years of growth in a row.
Daily figure as of 20 Nov 2026
Revenue (Annual rate)
24.5%
per year from 2013 to 2025, per share 16.6%
Earnings (Annual rate)
46.1%
per year from 2013 to 2025, per share 36.7%
Free cash flow (Annual rate)
no data
Growth per Year by Period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2013 | |
|---|---|---|---|
| Revenue | −6.4% | 25.8% | 24.5% |
| Revenue per share | −16.7% | 18.4% | 16.6% |
| Earnings | −32.1% | 31.7% | 46.1% |
| Earnings per share | −33.6% | 23.6% | 36.7% |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Growth Over Time
Revenue is 38.9% below its high of $2.44B in 2021. Since 2015 earnings grew faster than revenue, 31.7% against 25.8% a year, because the net margin rose from 6.4% to 10.2%. Intco Medical Technology has made a profit in every fiscal year since 2013. In the quarter to 30 Sep 2026 revenue grew 47.7% on the prior year quarter, after an average of 20.6% in the four quarters before.
Fiscal Years at a Glance
How Revenue and Earnings Grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2013 | $106.99M | $1.6M | $868.47K |
| 2014 | $132.71M | $4.78M | $4.16M |
| 2015 | $149.7M | $9.63M | −$10.21M |
| 2016 | $177.47M | $12.91M | −$20.53M |
| 2017 | $262.57M | $21.76M | $5.29M |
| 2018 | $283.88M | $26.9M | −$18.42M |
| 2019 | $312.44M | $26.75M | −$31.03M |
| 2020 | $2.08B | $1.05B | $855.25M |
| 2021 | $2.44B | $1.11B | $485.47M |
| 2022 | $992.07M | $94.36M | −$97.46M |
| 2023 | $1.04B | $57.45M | −$140.44M |
| 2024 | $1.43B | $219.82M | −$106.56M |
| 2025 | $1.49B | $151.6M | −$103.46M |
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Weak since 7 Nov 2026; valuation signal Fairly valued since 20 Nov 2026
- Price: closing price of 20 Nov 2026
- Amounts in US dollars at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
